Investment case
iShares Biotechnology ETF
IBB · 17 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 17 macro, policy, and market developments to iShares Biotechnology ETF since 2026-08-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for IBB yet, so no modelled value is shown. The IBB valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run IBB on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share
Improved sector sentiment and investor confidence. Similar to XBI, a strong biotech IPO can indicate a healthier funding environment and investor interest for the broader biotechnology industry, potentially attracting capital to diversified biotech ETFs.
· Moves sector sentiment, investor flow trends
- Main threat
Ionis slides over 40% year-to-date following late-stage clinical setbacks
Sector-wide sentiment. Similar to XBI, but IBB typically has a larger cap bias, so the direct impact from IONS might be slightly less pronounced, but the sentiment effect remains.
· Moves sector risk premium
- Open question
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology
Indirect impact through CLNN's weighting in the ETF and broader sector sentiment. Significant news from a component company can slightly influence the ETF, especially if it sets a trend for similar assets or technologies.
· Moves overall sector risk perception, investor sentiment towards early stage biotech
What changed, by assumption
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share
- 2026-09-21Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study
- 2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival
- 2026-08-12Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study
- 2026-08-21Werewolf Therapeutics and Ambros Therapeutics announce merger agreement and concurrent $150 million private placement
- 2026-09-24Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial | Bullish | 1-3m | 0.10 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share | Bullish | 1-3m | 0.50 |
| 2026-09-24 | Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology | watch | 1-3m | 0.20 |
| 2026-09-23 | Longeveron Announces Exploration of All Options to Maximize Shareholder Value Following Phase 2b Trial Results | Bearish | 1-5d | 0.10 |
| 2026-09-22 | XFLH Capital Corporation signs letter of intent for business combination with Renogen Biolab Inc. | watch | 3-12m | 0.20 |
| 2026-09-21 | Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study | Bullish | 1-5d | 0.10 |
| 2026-09-21 | Ionis slides over 40% year-to-date following late-stage clinical setbacks | Bearish | 1-5d | 0.15 |
| 2026-09-20 | Electra Therapeutics Sets Terms for $347M Nasdaq IPO | watch | 1-3m | 0.20 |
| 2026-09-19 | Electra Therapeutics IPO — $347M | watch | 1-3m | 0.10 |
| 2026-09-16 | COSCIENS Biopharma Inc. Convertible — $4.4M | watch | 1-3m | 0.20 |
| 2026-09-03 | NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival | Bullish | 1-5d | 0.50 |
| 2026-09-02 | TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy | watch | 1-3m | 0.10 |